Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: A pharmacokinetic-pharmacodynamic modelling approach

British Journal of Pharmacology

Volumn 153, Issue 1, 2008, Pages 164-174

  Lehr, T ^a   Staab, A ^b   Tillmann, C ^b   Nielsen, E O ^c   Trommeshauser, D ^b   Schaefer, H G ^b   Kloft, C ^a,d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c NEUROSEARCH A S   (Denmark)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Active metabolite; Alzheimer's disease; CNS; NS2330; Obesity; Parkinson's disease; Pharmacokinetic pharmacodynamic modelling; Potency; Tesofensine; WIN35,428

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CENTRAL NERVOUS SYSTEM AGENTS; NS 2330; TESOFENSINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; MOUSE; NONHUMAN; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CENTRAL NERVOUS SYSTEM AGENTS; COMPUTER SIMULATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MODELS, BIOLOGICAL;

EID: 37849050900     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707539     Document Type: Article

References (27)

1. Akaike H (1974). A new look at the statistical model identification. IEEE Trans Automatic Control 19: 716-723.
2. Barnard R, Gurevich KG (2005). In vitro bioassay as a predictor of in vivo response. Theor Biol Med Model 2: 3-11.
3. Beal SL, Sheiner LB (1998). NONMEM Users Guide. Conditional Estimation Methods. University of California: San Francisco.
4. Bergstrom KA, Tupala E, Tiihonen J (2001). Dopamine transporter in vitro binding and in vivo imaging in the brain. Pharmacol Toxicol 88: 287-293.
5. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M (2001). Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats -pharmacokinetic/pharmacodynamic modelling. Brit J Pharmacol 134: 1796-1804.
6. Carroll FI, Scheffel U, Dannals RF, Boja JW, Kuhar MJ (1995). Development of imaging agents for the dopamine transporter. Med Res Rev 15: 419-444.
7. FDA (1997). Guidance for industry drug interaction studies - study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/cder/Guidance/6695dft.htm, http://www.fda.gov/cder/Guidance/ 6695dft.pdf.
8. FDA (2004). Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html, http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf.
9. FDA (2005). Draft guidance for industry: safety testing of drug metabolites. http://www.fda.gov/Cder/guidance/6366dft.htm, http://www.fda.gov/ Cder/guidance/6366dft.pdf.
10. Gupta SK, Ellinwood EH, Nikaido AM, Heatherly DG (1990). Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiapines. I: Lorazepam. J Pharmacokinet Biopharm 18: 89-102.
11. Heykants J, Michiels M, Woestenborghs R, Awouters F, Leysen JE, Schuurkes J et al. (1988). Pharmacokinetic evaluation of the in vitro and in vivo pharmacological profile of the major metabolites of ketanserin in the rat. Arzneimittelforschung 38: 785-788.
12. Holford NH, Sheiner LB (1982). Kinetics of pharmacologic response. Pharmacol Ther 16: 143-166.
13. Holford NHG, Monteleone JPR, Kimko HC, Peck CC (2000). Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40: 209-234.
14. Johnson TN, Rosatami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT (2002). Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: A pharmacokinetic-pharmacodynamic analysis. Brit J Anaesth 89: 428-437.
15. Jonsson EN, Karlsson MO (1999). Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64.
16. Kerbusch T, Milligan PA, Karlsson MO (2004). Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic- pharmacodynamic data. Brit J Clin Pharmacol 57: 170-180.
17. Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG et al. (1999). Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology 144: 272-278.
18. Lehr T, Staab A, Tillmann C, Trommeshauser T, Raschig A, Schaefer HG et al. (2007). Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Brit J Clin Pharmacol 64: 36-48.
19. Lin JH, Chen IW, Lin TH (1994). Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: a study of L-663,581 and its metabolites in rats. J Pharmacol Exp Ther 271: 1197-1202.
20. Moghadamnia AA, Rostami-Hodjegan A, bdul-Manap R, Wright CE, Morice AH, Tucker GT (2003). Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs dextrorphan using quinidine inhibition. Brit J Clin Pharmacol 56: 57-67.
21. Pardridge WM(1998). CNS drug design based on principles of blood-brain barrier transport. J Neurochem 70: 1781-1792.
22. Stathis M, Scheffel U, Lever SZ, Boja JW, Carroll FI, Kuhar MJ (1995). Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology 119: 376-384.
23. Tatsumi M, Jansen K, Richelson E, Tatsumi M, Blakely RD (1999). Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 368: 277-283.
24. Thatte U (2001). NS-2330 NeuroSearch. Curr Opin Investig Drugs 2: 1592-1594.
25. Van Bree J, Nedelman J, Steimer JL, Tse F, Robinson W, Niederberger W (1994). Application of sparse sampling approaches in rodent toxicokinetics: a prospective view. Drug Inf J 28: 263-279.
26. Wu X, Gu HH (1999). Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233: 163-170.
27. Zuideveld KP, Rusic-Pavletic J, Maas HJ, Peletier LA, Van Der Graaf PH, Danhof M (2002). Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J Pharmacol Exp Ther 303: 1130-1137.